Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Flow Cytometry Assay Differentiates Active from Latent Tuberculosis

By LabMedica International staff writers
Posted on 02 Mar 2011
A flow cytometry-based assay identifies parameters of the immune response correlated to protection against tuberculosis (TB). More...


The assay derives functional signatures of immune responses to Mycobacterium tuberculosis (Mtb), the causative organism of TB, such as the cytokines and leucocytes, at different stages of the disease.

The new tool has been developed by scientists at the University of Lausanne, (Lausanne, Switzerland), that distinguishes between active and latent TB. A study recruited 283 participants from a hospital in Switzerland based on positive Mtb-specific interferon gamma (IFN-γ) enzyme-linked immunosorbent spot assay (Becton Dickinson, Allschwil, Switzerland). A validation cohort of 114 participants was obtained from two clinical sites from Switzerland and South Africa. For the flow cytometry analysis cells were stained with antibodies specific for a range of cytokines.

The scientists were able to show that the immune response by the cytokines such as tumor necrosis factor alpha (TNF-α), interleukin 2 (IL-2) and IFN-γ, were correlated to the different stages of tuberculosis disease. The flow cytometry-based assay read-out is focused on the immune response and not on microbiological parameters, thus explaining its reliability and quickness. The sensitivity of the assay was 62% and specificity was 92% for the different stages of TB. The results showed substantial increase in the proportion of single-positive TNF-α Mtb-specific CD4+ T cells, a type of white cell, in subjects with active disease. This parameter was the strongest predictor of diagnosis of active disease versus latent infection.

Giuseppe Pantaleo, MD, professor of medicine and lead author of the study, said, "This assay and the functional signatures of TB-specific immune responses are not only relevant for discriminating between active TB disease and latent infection, but may be also instrumental in monitoring the response to TB therapy." The authors concluded that although the flow cytometry-based assay requires specific equipment and skillful laboratory personnel, further technological development is already under way to make the assay widely accessible. The study was published online on February 20, 2011, in Nature Medicine.

Related Links:
University of Lausanne
Becton Dickinson


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.